Department of Neurology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
J Clin Neurosci. 2013 Aug;20(8):1114-6. doi: 10.1016/j.jocn.2012.10.026. Epub 2013 May 7.
Intravenous immunoglobulin (IVIg) is an essential treatment for many neurological, immunological and haematological conditions. However, the severity of its rare adverse effects is often underrecognised. We report a series of 15 patients receiving IVIg for neurological and immunological disorders who developed severe skin reactions. Despite pre-medication, nearly all patients ceased IVIg due to the severity of the adverse response. Interestingly, the majority of patients were male and two-thirds were receiving treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or another inflammatory or demyelinating neuropathy. This marked propensity for male patients with CIDP to develop significant dermatological reactions following IVIg administration has not previously been described. Mechanisms involving the underlying autoimmunity inherent to this condition may play a role.
静脉注射免疫球蛋白 (IVIg) 是治疗许多神经、免疫和血液疾病的重要手段。然而，其罕见的不良反应的严重程度往往被低估。我们报告了一系列 15 例因神经和免疫疾病接受 IVIg 治疗的患者，他们出现了严重的皮肤反应。尽管进行了预先用药，但几乎所有患者都因不良反应的严重程度而停止了 IVIg 治疗。有趣的是，大多数患者为男性，三分之二的患者正在接受慢性炎症性脱髓鞘性多发性神经病 (CIDP) 或其他炎症性或脱髓鞘性神经病的治疗。CIDP 男性患者在接受 IVIg 治疗后出现明显皮肤反应的这种明显倾向以前尚未被描述过。涉及到这种疾病固有自身免疫的机制可能起了作用。
